VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo

Stock Information for HTG Molecular Diagnostics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About HTG Molecular Diagnostics Inc.

VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update
VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update
VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo
VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202
VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update
VYNE Therapeutics Provides Update on VYN202 Program
VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.